TNFRSF9 and cancer: Our results are consistent with previous reports that have linked functional CD103+ DCs to therapy success in models of cancer immunotherapy with anti-CD137 and anti-PD-1 antibodies [38], of adoptive T-cell transfer therapy [39] and even of chemotherapy [40].